Arrowhead Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Fiscal first quarter ended December 31, 2021; comparative period is the three months ended December 31, 2020. Amounts below are in U.S. dollars unless otherwise stated.
Business context and financial performance
Arrowhead develops RNA interference medicines and is advancing a pipeline of wholly owned and partnered drug candidates. The quarter included initiation of the Phase 3 PALISADE study of ARO-APOC3, a license agreement with GSK for ARO-HSD, and continued expansion of research and manufacturing facilities.
| Metric | Q1 FY2022 | Q1 FY2021 |
|---|---|---|
| Revenue | $27.4 million | $21.3 million |
| Research and development expense | $65.8 million | $36.6 million |
| General and administrative expense | $25.0 million | $8.8 million |
| Operating loss | $63.3 million | $24.1 million |
| Net loss | $62.9 million | $20.7 million |
| Diluted loss per share | $0.60 | $0.20 |
| Cash used in operating activities | $61.3 million | $38.9 million |
Revenue increased about 29%, primarily from recognition of Takeda and Horizon collaboration revenue. The net loss widened as pipeline progression, clinical activity, discovery spending, and headcount increased. The filing does not present a meaningful gross margin measure for this business.
Liquidity, debt, and other key metrics
At December 31, 2021, Arrowhead reported $91.6 million of cash and cash equivalents, $112.5 million of short-term investments, $126.0 million of marketable securities, and $217.6 million of long-term investments—about $547.7 million in these balances combined. Cash and cash equivalents declined from $184.4 million at September 30, 2021. Total assets were $638.5 million and stockholders’ equity was $372.6 million.
The filing reports no borrowings or debt balance. Lease liabilities totaled $25.3 million ($2.8 million current and $22.5 million long-term). Management said current cash and investment resources were expected to fund operations for at least the next 12 months. Operating cash use was $61.3 million; investing cash use was $33.4 million, including $5.8 million of property and equipment purchases and net investment purchases. Financing cash inflow was $1.9 million, primarily from option exercises.
Material changes, outlook, and risks
- R&D expense rose 80%, led by candidate costs and discovery spending as programs advanced into later-stage trials. G&A expense rose 184%; stock-based compensation was a substantial contributor, including an expense increase associated with performance awards achieved earlier than anticipated and award modifications.
- Arrowhead entered a GSK license agreement for ARO-HSD with a $120 million upfront payment and potential milestones and royalties. Closing conditions were completed and the upfront payment received in January 2022; no related revenue or contract asset/liability was recognized at December 31, 2021.
- The company purchased 13 acres in Verona, Wisconsin and plans to invest $200–$250 million in manufacturing, laboratory, and office facilities. It also signed a 15-year lease for a planned San Diego facility, with rent commencement estimated for May 2023 and approximately $119 million of base rent over the initial term.
- Management expects R&D, facilities, and stock-based compensation costs to continue increasing as the pipeline and workforce expand. The filing provides no specific earnings or revenue guidance.
- COVID-19 had no significant financial impact in the quarter, but the company reported preclinical-program delays related to non-human-primate shortages and clinical enrollment delays. It also cited possible future effects from trial-site capacity, supplier operations, and the pandemic’s duration.
- Arrowhead remained eligible for $6.2 billion in aggregate development, regulatory, and sales milestones, plus royalties, under its licensing and collaboration agreements; these are contingent and not assured proceeds. Verona infrastructure reimbursements also depend on future tax revenues and are not guaranteed.
Most important facts for investors to verify
- Whether clinical enrollment and preclinical supply constraints affect trial timelines or development costs.
- The pace of cash use and whether the reported liquidity remains sufficient as clinical and facility spending expands.
- Timing and conditions for recognizing the $120 million GSK upfront payment and achieving future collaboration milestones.
- Actual total costs and timing for the Verona buildout and San Diego facility, including lease and operating commitments.
- Whether pipeline progress and partner decisions support the contingent milestone and royalty opportunities described in the filing.